Nicholas Reville
Article
Nicholas Reville is a recurring person in the Astral Codex Ten archive, appearing 3 times across 3 issues between July 29, 2024 and December 17, 2024. The archive places it in contexts such as “Nicholas Reville’s Center for Addiction Science Policy & Research”; “Nicholas Reville (of the Recursive Adaptation Substack)”; “Nicholas Reville of Recursive Adaptation has published his Innovation Agenda For Addiction”. It most often appears alongside ACX, Christianity, FDA.
Metadata
- Category: People
- Mention count: 3
- Issue count: 3
- First seen: July 29, 2024
- Last seen: December 17, 2024
Appears In
Related Pages
-
- ACX (2 shared issues)
-
- Christianity (2 shared issues)
-
- FDA (2 shared issues)
-
- NYT (2 shared issues)
-
- Ozy (2 shared issues)
-
- Richard Hanania (2 shared issues)
-
- Russia (2 shared issues)
-
- SBF (2 shared issues)
-
- Substack (2 shared issues)
-
- Trump (2 shared issues)
-
- US (2 shared issues)
-
- 1906 SF earthquake (1 shared issues)
External Links
Source Context
Recovered passages from the original issue text. When the raw archive preserved outbound links inside the source passage, they are listed directly under the quote.
2: I plan to write about GLP-1 receptor agonists for addiction pretty soon. Nicholas Reville’s Center for Addiction Science Policy & Research is one of the first organizations thinking about this from a public policy perspective, and they’re looking for a COO / Strategy Director.
Inline links: looking for a COO / Strategy Director
31: Related: Nicholas Reville (of the Recursive Adaptation Substack) has finally gotten a coalition together to do formal clinical trials of GLP-1RAs for addiction:
52: Nicholas Reville of Recursive Adaptation has published his Innovation Agenda For Addiction, sort of the Progress Studies-ish take on the opioid crisis and how to solve it. The main points are deploying GLP-1RAs for their anti-addictive effects, giving addiction medicines a special fast-track through the FDA, and various government incentives / advance purchase commitments / partnerships. Even aside from the plan, this is interesting to read for its examination of perverse incentives in medicine - for example, pharma companies are reluctant to develop anti-addiction medications because they don't want to be seen as "profiting off a crisis", and they don't want to study their existing medications for addiction because the studies might reveal new side effects that would harm their existing business. Everything here seems reasonable, but my main worry is that a lot of it is zero-sum - the FDA only has so much review capacity, spending it on addiction meds would decrease it for other meds, and I worry that every disease is so bad that "redirect the FDA to focus on this in particular!" sounds pretty good when you think about it on its own. I am more excited about finding ways to streamline it in general - but don't begrudge advocates for particular conditions for wishing they had an easier time.
Inline links: Innovation Agenda For Addiction